Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2021-03-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
独立董事提名人声明
Board/Management Information Classification · 95% confidence The document is a formal public statement from the board of Shenzhen Xinlitai Pharmaceutical Co., Ltd. nominating an individual as an independent director candidate. It contains detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and independence criteria. There is no financial data, earnings information, or report content. The document is not an annual report, earnings release, or management discussion. It is a regulatory announcement related to board nominations and governance compliance. This fits best under Board/Management Information (MANG), which covers announcements of changes or nominations in the company's board of directors.
2021-03-29 Chinese
控股股东及其他关联方占用资金情况审核报告
Audit Report / Information Classification · 95% confidence The document is an audit report issued by a certified public accounting firm regarding the company's related party fund occupation situation for the year 2020. It includes an audit opinion, responsibilities of management and auditors, and a detailed summary table of funds occupied by controlling shareholders and related parties. The document references an audit report number and is intended to be used as a mandatory attachment to the company's annual report. It contains substantive financial data and audit conclusions but is not the full annual report itself. This fits the definition of an Audit Report / Information (AR), as it is a standalone audit report focusing on a specific aspect of the company's financials (related party fund occupation). The document length (4007 characters) and content confirm it is not merely an announcement or certification but a full audit report on this matter. FY 2020
2021-03-29 Chinese
2020年度独立董事述职报告（韩文君）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2020" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's activities, attendance, opinions, committee work, inspections, training, and suggestions during the 2020 term. The content focuses on the director's duties and governance-related activities rather than financial results or audit opinions. It is a report by a board member about their role and responsibilities, which fits the category of Board/Management Information (MANG). The document length is short (1225 characters), but it is a substantive report, not merely an announcement or certification. Therefore, the best classification is MANG.
2021-03-29 Chinese
关于子公司对外投资、境外子公司股权架构调整暨向子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's subsidiary investment, overseas subsidiary equity structure adjustment, and capital increase to a subsidiary. It includes specifics about the establishment of new subsidiaries, acquisition of shares, capital injection, board approval, and risk factors. The document is not a full financial report but an announcement of a corporate transaction involving capital structure and investment activities. It does not contain comprehensive financial statements or quarterly/yearly financial results. The content fits the category of Capital/Financing Update (CAP) as it relates to investment and capital changes within the company's subsidiaries.
2021-03-29 Chinese
关于使用自有闲置资金投资理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the use of its own idle funds to invest in low-risk, short-term financial products. It details the board meeting approval, investment purpose, amount, types of products, risk analysis, and opinions from independent directors and the supervisory board. The document is a formal public announcement about a financing-related decision but does not contain financial statements or detailed financial performance data. It is not a full financial report, earnings release, or management discussion. The content fits best under Capital/Financing Update (CAP) as it relates to the company's capital management and investment of idle funds in financial products.
2021-03-29 Chinese
第五届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 12th meeting of the 5th Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes approval of the 2020 annual general manager work report, the 2020 board work report, the 2020 annual report and its summary, profit distribution plan, appointment of the audit firm for 2021, changes in accounting policies, nomination of independent directors, and other corporate governance matters. The document also references the 2020 annual report and other reports that will be submitted to the 2020 annual shareholders meeting for approval. The content is focused on board meeting resolutions and management reports rather than the full annual report itself. The document length is about 9,834 characters, which is substantial but the content is primarily about board decisions and approvals rather than the full financial statements or comprehensive annual report. Therefore, this document fits best under the category of Board/Management Information (MANG), as it announces board meeting resolutions and management reports rather than being the full Annual Report (10-K) or Audit Report (AR).
2021-03-29 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.